Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Two new appointments at Biovail

This article was originally published in Scrip

Executive Summary

Biovail (Canada) has appointed Peggy Mulligan chief financial officer and Dr Neil Sussman vice-president of neurologic and psychiatric development at Biovail Technologies. Mrs Mulligan succeeds Adrian De Saldanha, who had been serving as Biovail's interim chief financial officer; she most recently served as a principal at Priiva Consulting. Dr Sussman was previously president of NMSNeuro Consulting, specialising in therapeutic areas such as dementia, mania, neuroprotection, multiple sclerosis and Parkinson's disease. Before that, he was senior director of CNS clinical research at Kyowa Pharmaceutical.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC003126

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel